Cargando…

What can we learn from the effect of trihexyphenidyl on motor fluctuations during continuous levodopa-carbidopa intestinal gel infusion (LCIG)? – First documented case

Motor fluctuations can be seen even during treatment with continuous levodopa-carbidopa intestinal gel infusion (LCIG). We report on a middle-aged man with advanced Parkinson's disease (PD) on LCIG in which motor fluctuations have been improved with an anticholinergic. To the best of our knowle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubo, Shin-ichiro, Nakamura, Ken, Tada, Yoshimasa, Kashio, Nobuyuki, Yamashita, Shinya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298791/ https://www.ncbi.nlm.nih.gov/pubmed/34316650 http://dx.doi.org/10.1016/j.prdoa.2020.100071

Ejemplares similares

Rescue levodopa‐carbidopa intestinal gel (LCIG) therapy in Parkinson’s disease patients with suboptimal response to deep brain stimulation
por: Elkouzi, Ahmad, et al.
Publicado: (2019)

Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
por: De Fabregues, Oriol, et al.
Publicado: (2017)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
por: Noui, Yassine, et al.
Publicado: (2021)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
por: Bergquist, Filip, et al.
Publicado: (2022)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study
por: Moes, Harmen R., et al.
Publicado: (2020)

Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion
por: Kilinçalp, Gökçe, et al.
Publicado: (2022)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2017)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson’s Disease Treatment
por: Nomoto, Yusuke, et al.
Publicado: (2023)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

Proposition of zinc supplementation during levodopa–carbidopa intestinal gel treatment
por: Matsuyama, Hirofumi, et al.
Publicado: (2018)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin, Viorelia Adelina, et al.
Publicado: (2020)

Phytobezoar Associated with Levodopa-carbidopa Intestinal Gel Infusion in Patients with Parkinson's Disease: A Case Report and Literature Review
por: Ueno, Tatsuya, et al.
Publicado: (2021)

Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion
por: Garrì, Federica, et al.
Publicado: (2022)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2017)

Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
por: Lang, Anthony E., et al.
Publicado: (2015)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
por: Bautista, Juan Miguel Pilar, et al.
Publicado: (2020)

Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
por: GÜLTEKİN, Murat, et al.
Publicado: (2020)

24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations
por: Thakkar, Sandeep, et al.
Publicado: (2021)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
por: Pauls, K. Amande M., et al.
Publicado: (2021)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience
por: Băjenaru, O., et al.
Publicado: (2015)

Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion
por: Garrì, Federica, et al.
Publicado: (2022)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report
por: Torres, Viviana, et al.
Publicado: (2022)

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa‐carbidopa Intestinal Gel
por: Fernandez, Hubert H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j2i4719ka46nja36nttnqvv455